Newamsterdam Pharma Company N.V. (NAMS)

$28.62 -1.20 (-4.02%)
Market Cap 3.29B
Revenue (ttm) 22.50M
Net Income (ttm) -203.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -905.87%
Debt to Equity Ratio 0.00
Volume 965,000
Avg Vol 781,018
Day's Range N/A - N/A
Shares Out 114.98M
Stochastic %K 2%
Beta 0.04
Analysts Strong Sell
Price Target $49.33

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 35 206 2971
Address:
Gooimeer 2-35, Naarden, Netherlands
augie0030
augie0030 Mar. 14 at 12:42 AM
$ESPR shorts should move on to $NAMS now that the esperion short thesis is no longer a viable play and we are launching to the moon
0 · Reply
wRsYUeX
wRsYUeX Mar. 13 at 10:15 PM
$ESPR If we had a top tier CEO with credibility with Research Analysts and Institutional Shareholders, at minimum, we would have similar valuation as $NAMS. The Board of Directors is stacked with former colleagues and appointees of Sheldung. We all know who they are an they know what disservice they are doing to ESPR Shareholders.
1 · Reply
kemah
kemah Mar. 13 at 6:02 PM
$ESPR $NAMS New Amsterdam Pharma sits at a $3.5B market cap — 7× larger than $ESPR. They have no approved drug, no revenue, and are still in trials. Meanwhile $ESPR has an approved product and sales… yet trades at a fraction of the valuation. 7× the value for a company selling nothing. Let that sink in.
1 · Reply
masonat
masonat Mar. 9 at 1:18 PM
$NAMS Watch out for the SPINOZA trial 👀 That's about all the additional details so far 🤷🏻
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 9 at 1:00 PM
$NAMS ceo hinting that ada + mace data may not be that great with $MRK's enlicitide. keep an eye out for this data drop.
2 · Reply
newfguy
newfguy Mar. 6 at 4:43 PM
$NAMS volume down today. thank you weak hands!
0 · Reply
newfguy
newfguy Mar. 5 at 9:02 PM
$NAMS "In short, this sale represented less than 10% of his total equity/options exposure to NAMS and the sale was due to personal/family reasons, not due to any lack of faith in the business or long-term potential of obicetrapib.", NAMS response to my inquiry about CEO stock sale.
1 · Reply
Dave_100
Dave_100 Mar. 5 at 5:21 PM
$NAMS I haven’t seen anyone comment on the CEO selling what looked to be 52% of his holdings on 3/2 just after he sold another significant stake in late February. This seems to be significantly more than selling to cover potential taxes on vested options or RSU’s.
4 · Reply
masonat
masonat Mar. 5 at 4:14 PM
$NAMS Bought some of my shares back.
1 · Reply
8869scy
8869scy Mar. 4 at 4:29 PM
$NAMS a statin alternative for cholesterol is nice but I'm really here for potential use to treat (maybe not by itself but as a part of a therapy) Alzheimer's / apoe4 carriers
0 · Reply
Latest News on NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2026, 4:01 PM EST - 9 days ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Feb 25, 2026, 8:00 AM EST - 18 days ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 7:00 AM EST - 25 days ago

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 4, 2026, 8:00 AM EST - 5 weeks ago

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Jan 9, 2026, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 6:33 PM EST - 3 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 25, 2025, 8:00 AM EST - 3 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

Nov 16, 2025, 10:30 AM EST - 4 months ago

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 5, 2025, 8:00 AM EST - 4 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Oct 30, 2025, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 24, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 10:22 PM EDT - 6 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 25, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 21, 2025, 2:41 AM EDT - 7 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 18, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30, 2025, 8:25 AM EDT - 8 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 9, 2025, 7:00 AM EDT - 9 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Jun 5, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 27, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 8, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 7, 2025, 7:15 AM EDT - 11 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Apr 30, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 11:26 PM EST - 1 year ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 28, 2025, 10:48 AM EST - 1 year ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 1:33 PM EST - 1 year ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 11:14 AM EST - 1 year ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 9, 2024, 8:00 AM EDT - 2 years ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Apr 1, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 25, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Mar 12, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 10:40 PM EST - 2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

augie0030
augie0030 Mar. 14 at 12:42 AM
$ESPR shorts should move on to $NAMS now that the esperion short thesis is no longer a viable play and we are launching to the moon
0 · Reply
wRsYUeX
wRsYUeX Mar. 13 at 10:15 PM
$ESPR If we had a top tier CEO with credibility with Research Analysts and Institutional Shareholders, at minimum, we would have similar valuation as $NAMS. The Board of Directors is stacked with former colleagues and appointees of Sheldung. We all know who they are an they know what disservice they are doing to ESPR Shareholders.
1 · Reply
kemah
kemah Mar. 13 at 6:02 PM
$ESPR $NAMS New Amsterdam Pharma sits at a $3.5B market cap — 7× larger than $ESPR. They have no approved drug, no revenue, and are still in trials. Meanwhile $ESPR has an approved product and sales… yet trades at a fraction of the valuation. 7× the value for a company selling nothing. Let that sink in.
1 · Reply
masonat
masonat Mar. 9 at 1:18 PM
$NAMS Watch out for the SPINOZA trial 👀 That's about all the additional details so far 🤷🏻
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 9 at 1:00 PM
$NAMS ceo hinting that ada + mace data may not be that great with $MRK's enlicitide. keep an eye out for this data drop.
2 · Reply
newfguy
newfguy Mar. 6 at 4:43 PM
$NAMS volume down today. thank you weak hands!
0 · Reply
newfguy
newfguy Mar. 5 at 9:02 PM
$NAMS "In short, this sale represented less than 10% of his total equity/options exposure to NAMS and the sale was due to personal/family reasons, not due to any lack of faith in the business or long-term potential of obicetrapib.", NAMS response to my inquiry about CEO stock sale.
1 · Reply
Dave_100
Dave_100 Mar. 5 at 5:21 PM
$NAMS I haven’t seen anyone comment on the CEO selling what looked to be 52% of his holdings on 3/2 just after he sold another significant stake in late February. This seems to be significantly more than selling to cover potential taxes on vested options or RSU’s.
4 · Reply
masonat
masonat Mar. 5 at 4:14 PM
$NAMS Bought some of my shares back.
1 · Reply
8869scy
8869scy Mar. 4 at 4:29 PM
$NAMS a statin alternative for cholesterol is nice but I'm really here for potential use to treat (maybe not by itself but as a part of a therapy) Alzheimer's / apoe4 carriers
0 · Reply
masonat
masonat Mar. 4 at 3:44 PM
$NAMS You should always be suspicious of U-shaped curves in observational studies. The same type of studies also show low LDL and low glucose are bad. Just reverse causation nonsense. In Broadway, people with HDL >100 had lowest MACE. We of course also saw anacetrapib (which also boosted HDL 100%) trial which was followed out 6 years. MACE reduction got larger over time.
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 4 at 2:17 PM
$NAMS
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 4 at 1:59 PM
$NAMS
0 · Reply
Phasedrei
Phasedrei Mar. 4 at 1:45 PM
$NAMS Why is there no mention here of the 135% increase in HDL? At the time, this was discussed as one reason for the failure of all other CETP inhibitors. I am therefore very interested to see the long-term data. HDL's influence on risk reduction shows a U-shaped curve. It is suspected that excessively high HDL levels could have a proatherogenic effect
3 · Reply
outlawinvestor1
outlawinvestor1 Mar. 4 at 1:37 PM
$NAMS td cowen healthcare conference panel.
0 · Reply
newfguy
newfguy Mar. 4 at 12:30 AM
$NAMS another great entry point for what will be a very successful company
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 3 at 11:37 PM
$NAMS td cowen healthcare conference: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/krCq8ViYjALFCWrGYZsYbK
0 · Reply
masonat
masonat Mar. 3 at 9:45 PM
$NAMS If I heard correctly on the call today, alzheimer's study details should be coming very soon.
0 · Reply
Finlay2
Finlay2 Mar. 2 at 2:49 PM
$NAMS A ton of volume early and dropping fast. Any new news?
2 · Reply
masonat
masonat Feb. 27 at 1:30 PM
$NAMS Brooklyn results published in Nature. https://www.nature.com/articles/s41591-025-04179-4
0 · Reply
BlackForge
BlackForge Feb. 22 at 12:48 AM
$NAMS is developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in high‑risk cardiovascular patients a potential blockbuster class if approved…
0 · Reply
riskalex
riskalex Feb. 20 at 3:53 PM
$NAMS New Amsterdam Acquisition is a SPAC with dormant valuation. Capital preservation is the base case absent a merger. Upside depends on deal quality.
1 · Reply